They’re two of the biggest names in the pharmaceutical industry, and now GlaxoSmithKline (GSK) has announced that it’s teaming up with Sanofi to develop a coronavirus vaccine.
The firms hope that combining resources could result in a vaccine by the middle of next year. Sanofi will contribute its S-protein Covid-19 antigen, which is based on recombinant DNA technology.
This technology has produced an exact genetic match to proteins found on the surface of the virus. GSK will contribute its pandemic adjuvant technology to the collaboration.
An adjuvant is added to some vaccines to enhance the immune response, and has been shown to create a stronger and longer lasting immunity against infections than the vaccine alone.